At what stage is this treatment used?
- Aflibercept (Zaltrap®) is a type of targeted drug known as a fusion protein. This drug is designed to target multiple growth factors involved in cancer and angiogenesis, specifically proteins called VEGF-A, VEGF-B and a related protein called placental growth factor (PlGF). Aflibercept is approved for use as treatment in second-line therapy in combination with chemotherapy (FOLFIRI) for advanced (metastatic) colorectal cancer.
Is this drug available via the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?
- Aflibercept is not currently listed on the PBS as a subsidised treatment.
Download the Consumer Medicine Information (CMI) for Zaltrap